Find Clinical Trials

Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer

Principal Investigator: David Hufnagel, DO

A Study Looking at the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide

Principal Investigator: David Hufnagel, DO

Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Principal Investigator: David Hufnagel, DO

Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant (BYLieve)

Principal Investigator: Ike Onwere, MD

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy

Principal Investigator: David Hufnagel, DO

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Principal Investigator: Michael Wahl, MD

Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Principal Investigator: David Hufnagel, DO

Crizotinib in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Principal Investigator: David Hufnagel, DO

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Principal Investigator: David Hufnagel, DO

Nivolumab After Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer (ANVIL)

Principal Investigator: David Hufnagel, DO

Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Principal Investigator: Michael Wahl, MD

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Principal Investigator: David Hufnagel, DO

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Principal Investigator: Wei Bai, MD

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Principal Investigator: David Hufnagel, DO

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Principal Investigator: David Hufnagel, DO

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Principal Investigator: Ike Onwere, MD

Click here for more information on this trial.

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PARALLAX)

Principal Investigator: Sridhar Vijayasekaran, MD

Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI)

Principal Investigator: Edward Toggart, MD

SJM MRI Diagnostic Imaging Registry (IDE)

Principal Investigator: Jeff Hsing, MD

Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles

Principal Investigator: Sugat Patel, MD

Exercise and Insulin Signaling in Human Skeletal Muscle

Samaritan Health Services Principal Investigators: Craig Graham, MD, Nicholas Phillips, MD, and Josh Lenhof, DO

Oregon State University Principal Investigators: Sean Newsom, PhD, and Matthew Robinson, PhD